Q-omics provides the consensus-scored MPZ profile across patient tissues and cancer cell-line models. MPZ expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MPZ is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, MPZ RNA expression shows 15,673 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UVM, BLCA, and KIRP as cancer lineages where MPZ shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MPZ — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MPZ survival associations across molecular data types. MPZ RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MPZ RNA expression–survival associations across cancer types. High MPZ expression shows unfavorable associations in LUAD, LGG, KIRP and LIHC, but favorable associations in UVM and PAAD. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MPZ RNA expression.
This table summarizes MPZ tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in BLCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for MPZ. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MPZ shows lower tumor expression in BLCA, COAD, KICH, READ and BRCA and higher tumor expression in LIHC. The BLCA box plot shows higher MPZ RNA expression in normal versus tumor tissue (log2 FC = −2.395, t-test p < 0.001).
This table shows molecular features associated with MPZ in patient tissues and cancer cell lines. In patient samples, MPZ shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, MPZ RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SKIN.
